



TITLE:

Hemostasis management of tooth extraction in a patient with Bernard–Soulier syndrome and a severe bleeding tendency: A case report

AUTHOR(S):

Mishima, Sayaka; Nakao, Kazumasa; Ikeno, Masayuki; Bessho, Kazuhisa

CITATION:

Mishima, Sayaka ...[et al]. Hemostasis management of tooth extraction in a patient with Bernard–Soulier syndrome and a severe bleeding tendency: A case report. *Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology* 2015, 27(4): 525-528

ISSUE DATE:

2015-07

URL:

<http://hdl.handle.net/2433/207519>

RIGHT:

© 2014. This manuscript version is made available under the CC-BY-NC-ND 4.0 license <http://creativecommons.org/licenses/by-nc-nd/4.0/>; The full-text file will be made open to the public on 1 July 2016 in accordance with publisher's 'Terms and Conditions for Self-Archiving'; This is not the published version. Please cite only the published version.; この論文は出版社版ではありません。引用の際には出版社版をご確認ください。

Article type : Case report

Article title : Hemostasis management of tooth extraction in a patient with Bernard–Soulier syndrome and a severe bleeding tendency: A case report

Short title : Hemostasis and Bernard–Soulier syndrome

Sayaka Mishima*, Kazumasa Nakao, Masayuki Ikeno, Kazuhisa Bessho

Department of Oral and Maxillofacial Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

*Corresponding author:

Sayaka Mishima

Department of Oral and Maxillofacial Surgery, Faculty of Medicine, Kyoto University, 54 Kawahara, Sakyou-ku, Kyoto, Japan

Tel.: +81 (75) 751-3729; Fax: +81 (75) 751-4550

E-mail address: sayakams@kuhp.kyoto-u.ac.jp

Conflict of interest : None

Informed consent : Obtained

ABSTRACT

Bernard–Soulier syndrome is characterized by thrombocytopenia, giant platelets, and severe bleeding; although bleeding varies widely, it is usually evident from childhood and requires particular attention during surgeries. We extracted a fractured tooth and performed hemostasis management in a male patient with a Bernard–Soulier syndrome-related severe bleeding tendency after intracerebral hemorrhage. The preoperative platelet count was abnormally low ($7 \times 10^9/L$). Normal coagulability was observed. After intravenous hydrocortisone administration, he received 10 human leukocyte antigen-matched platelet units. The extraction sites were packed with gelatine sponges and a splint was used for hemostasis. Excellent hemostasis was achieved with minimal human leukocyte antigen-matched platelets.

KEYWORDS

Bernard–Soulier syndrome
HLA-matched platelets
Optics method in fluorescent platelet channel
Bleeding tendency
Hemostasis management

1 INTRODUCTION

2 Bernard–Soulier Syndrome (BSS) is a very rare, autosomal-recessive inherited disorder
3 characterized by thrombocytopenia, giant platelets, severe bleeding, and deficient
4 ristocetin-induced platelet aggregation[1]. BSS occurs extremely rarely in European, North
5 American, and Asian populations, which have been studied most intensively; a prevalence of
6 $<1/1000,000$ has been estimated from the cases reported previously. In Japan, 68 cases have
7 been registered through a national investigation. BSS-associated bleeding symptoms, such as
8 skin ecchymosis, epistaxis, and gingival bleeding, are caused by platelet reduction and
9 dysfunction and they usually present in early childhood; more severe episodes are associated
10 with surgical procedures, dental extractions, menses, and accident[2]. We report hemostasis
11 management and tooth extraction in a patient with severe BSS-related bleeding.

12

13 CASE REPORT

14 A 40-year-old male underwent extraction of the second left maxillary molar while receiving
15 platelet transfusion. He had repeated nosebleeds from 1 year of age and had been diagnosed
16 with idiopathic thrombocytopenic purpura (ITP) because of thrombocytopenia (bone marrow
17 megakaryocytes were in the normal range) and had received whole blood or platelet
18 concentrate transfusions for hemostasis. He was diagnosed with BSS at 17 years of age via
19 evaluation of blood smears containing giant platelets and a biochemical flow cytometric
20 platelet surface assessment that revealed a defective platelet membrane GPIb-X-V complex.
21 His parents and sons had no bleeding histories, but his parents had a consanguineous marriage.
22 His previous history was as follows: at 7 years of age, he suffered from epilepsy and began
23 using phenobarbital. At 14 years of age, his epileptic symptoms disappeared and he stopped
24 treatment. At 25 years of age, he was diagnosed with chronic hepatitis C consequent to
25 frequent blood transfusion during childhood. At 39 years of age, he had cerebral hemorrhage

and required transfusion of 90 platelet units [platelet concentrate, 10 units; human leukocyte antigen (HLA)-matched platelets, 40 units, and cross-matching HLA-matched platelets, 40 units] as conservative therapy.

He had an average built with good nourishment. The skin and oral mucosa revealed no ecchymosis or petechiae. An oral examination revealed poor hygiene with redness and swelling of the maxillary and mandibular gingiva and dental calculus on most teeth. Blood clots were observed around the second right maxillary premolar (Fig 1-a). The second left maxillary molar was cracked and decayed to the dental pulp (Fig 1-b). The preoperative platelet count was abnormally low ($7 \times 10^9/L$), measured using the automated hematology analyzer XN-9000 (Sysmex, Kobe, Japan) with the impedance measuring method in the whole-blood mode. This low platelet count was automatically converted and measured via the optics method in the fluorescent platelet channel (PLT-F) for a value of $17 \times 10^9/L$. Normal blood coagulability was evidenced from the following: prothrombin time, 11.4 s; international normalized ratio, 0.93; and activated partial thromboplastin time, 28.5 s. The liver function was slightly deteriorated as indicated by the following: aspartate aminotransferase, 36 U/L; alanine aminotransferase, 61 U/L; and gamma glutamyl transferase, 71 U/L.

Giant platelets were detected in the pathological blood smear; these platelets were slightly larger than red blood cells (Fig. 2). In a biochemical assessment, the reduced levels of platelet membrane glycoproteins GPIX and GPIb α were detected via flow cytometry.

In October 2013, the second left maxillary molar was extracted with platelet transfusion. To prevent an allergic reaction, we administered hydrocortisone before extracting the patient's left maxillary molar while transfusing 10 units of HLA-matched platelets. The tooth was

removed surgically, and little bleeding was observed. The extraction sites were packed with gelatine sponges and a splint was used for hemostasis (Fig 3-a,b). The postoperative PLT-F count increased to an estimated $37 \times 10^9/L$. Further examination revealed deficient ristocetin-induced platelet aggregation before and after transfusion (Table 1). Three days after extraction, we removed the extraction site hematoma under local anaesthesia and adjusted the splint, which did not fit the extraction sites because of the hematoma (Fig 3-c). Seven days after extraction, continuous bleeding from the palatal side of the gingival margin and an infection of the buccal side of the gingival margin were identified at the extraction site. We initiated carbazochrome sodium sulfonate hydrate and tranexamic acid treatment along with antibiotics. Eleven days later, secondary healing was achieved at the extraction site with no bleeding, indicative of excellent hemostasis.

DISCUSSION

Congenital platelet disorders related to adhesion, activation, secretion, aggregation or number are often indistinguishable from various coagulopathies solely according to clinical manifestations[2]. As in our patient, BSS—a congenital platelet disorder—is frequently misdiagnosed as ITP because of the prolonged bleeding time and thrombocytopenia and often is treated unsuccessfully with steroids or splenectomy. BSS-associated bleeding usually presents as minor symptoms such as epistaxis and frequent gingival bleeding; potential fatality due to bleeding (e.g., cerebral bleeding) is very rare[3]; however, our case was among these rare cases. BSS-associated bleeding is considered to be caused by qualitative or quantitative defects or reductions in the platelet membrane GPIb-X-V complex, a primary platelet adhesion receptor [1, 4]. Our patient was diagnosed with BSS after a flow cytometric biochemical platelet assessment to detect the platelet membrane GPIb-X-V complex. In this case, the appearance of giant platelets in the pathological blood smear examination

confirmed the diagnosis; these platelets may be excluded from impedance counts, thus yielding falsely low values. Accordingly, platelets in such cases are counted via visual microscopic evaluation.

Recent attention has been given to an available automatic optics measurement method in PLT-F. This method performs hematological analyses via flow cytometry with a semiconductor laser. Platelets are analyzed in a two-dimensional scattergram in which the X-axis represents the intensity of the side-scattered fluorescent light (SFL) and the Y-axis represents the intensity of the forward-scattered light (FSC). SFL provides information on the degree of blood cell staining, whereas FSC provides information on the blood cell size (Fig. 4). In our case, we measured the patient's platelet count using an automated hematology analyzer (XN-9000) with an automatic retesting function. Impedance measurement yielded a preoperative platelet count of $7 \times 10^9/\text{L}$, whereas the optics method yielded a value of $17 \times 10^9/\text{L}$; given this increase, the giant platelet count was estimated as $1 \times 10^9/\text{L}$. The optical platelet count correlated strongly with the reference flow cytometric method, particularly at platelet counts of $<100 \times 10^9/\text{L}$. At this level, the optics method is far more reliable than impedance counting and will thus facilitate more appropriate clinical decisions, particularly with regard to platelet transfusion[5]. This system also improves workflow efficiency and confidence in abnormal sample results in routine hematology laboratories[6].

Many factors affect bleeding time reproducibility. The results are highly operator-dependent, with significant inter-operator variability[7]. Normal skin bleeding times range from 1 to 3 min; however, skin bleeding times have been found to be inaccurate and non-reproducible. In our case, this time was marginally prolonged to 5 min before transfusion. We expected time reduction after transfusion but instead observed an increase to 7 min. Therefore, the bleeding

1 times were not consistent with the clinical bleeding symptoms. This suggests difficulty in
2 diagnosing hematologic diseases from only the skin bleeding time. Platelet aggregation tests
3 were considered valuable for the differential diagnosis of congenital platelet disorders.
4 However, the results of such examinations vary because of the blood collection and
5 platelet-rich plasma techniques, interval from blood collection to examination, and inducer
6 stability. Therefore, re-examination of abnormal values is required for confirmation[8].

7
8 Hemostasis or prophylaxis for bleeding prevention during surgical procedures usually
9 requires transfusion of blood and/or platelets, despite the risk that the patients will develop
10 antiplatelet and/or anti-erythrocyte alloantibodies[2,9]. We should therefore minimize platelet
11 transfusion because antiplatelet reactions are known to reduce the effects of hemostasis. In
12 our case, chronic hepatitis C and previous intracerebral hemorrhage aggravated the bleeding
13 tendency. We expected postprocedural hemostatic difficulties due to severe thrombocytopenia
14 and platelet dysfunction. The patient had received HLA-matched platelet transfusions to treat
15 intracerebral hemorrhage. Consequently, we prepared the same HLA-matched platelets when
16 planning platelet transfusion. Using antifibrinolytic drugs such as ϵ -aminocaproic acid or
17 tranexamic acid may or may not be beneficial. The different responses of individual patients
18 to these latter measures may reflect differences in the underlying disease; those with milder
19 forms are more likely to respond to these therapies[2]. In our case, little postprocedural
20 bleeding continued for some days. We avoided additional postoperative HLA-matched
21 platelet transfusion using a splint and by administering carbazochrome sodium sulfonate
22 hydrate and tranexamic acid.

23
24 There have been some reports regarding the perioperative management of patients with BSS
25 in oral and maxillofacial surgery. Hartman et al[9] presented a patient with BSS who

underwent third molar extractions; treatment with preoperative and intraoperative systemic aminocaproic acid, seven HLA-matched platelet units, and topical gelfoam and thrombin resulted in sustained hemostasis and a durable healing response. Yoshiga et al[10] presented a patient with BSS who underwent ameloblastoma enucleation under general anesthesia; intravenous hydrocortisone administration prevented an allergic reaction to transfusion, which was initiated platelet transfusion. Total 15 HLA-matched platelet units were administered to avoid alloimmunization. The operation was completed without abnormal bleeding, and the postoperative course was good without bleeding[10].

In conclusion, we extracted a tooth and transfused overall 10 HLA-matched platelet units, using gelatine sponges and a splint for hemostasis. Frequent platelet transfusion makes antibodies that correspond to HLA on platelets. It is known that increase in the number of antibodies to transfused platelets causes reduction in hemostatic effect. In this case, we prepared HLA-matched platelets. Persistent bleeding from the extraction sites was recognized and treated with carbazochrome sodium sulfonate hydrate and tranexamic acid along with antibiotics. Accordingly, we avoided additional postoperative platelet transfusion and achieved wound healing.

ACKNOWLEDGMENTS

We would like to thank Dr. Takayama (Takashima Municipal Hospital), Dr. Shindou (Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University), and Ms. Nakanishi (Department of Clinical Laboratory, Faculty of Medicine, Kyoto University) for their assistance.

1 REFERENCES

- 2 [1] Nurden AT, Caen JP. Specific roles for platelet surface glycoproteins in platelet
3 function. *Nature* 1975;255:720-2
- 4 [2] Lopez JA, Andrews RK, Afshar-Kharghan V, Berndt MC. Bernard-Soulier
5 syndrome. *Blood* 1998;91:4397-418.
- 6 [3] Toogeh G, Keyhani M, Sharian R, Safaee R, Emami A, Dalili H. A study of
7 Bernard-Soulier syndrome in Tehran, Iran. *Arch Iran Med* 2010;13:549-51.
- 8 [4] Berndt MC, Gregory C, Chong BH, Zola H, Castaldi PA. Additional glycoprotein defects
9 in Bernard-Soulier's syndrome: confirmation of genetic basis by parental analysis. *Blood*
10 1983;62:800-7.
- 11 [5] Briggs C, Harrison P, Grant D, Staves J, Machin SJ. New quantitative parameters on a
12 recently introduced automated blood cell counter—the XE2100™. *Clin Lab Haem*
13 2000;22:345-50.
- 14 [6] Briggs C, Longair I, Kumar P, Singh D, Machin SJ. Performance evaluation of the Sysmex
15 hematology XN modular system. *J Clin Pathol* 2012;62:1024-30.
- 16 [7] Gewirtz AS, Kottke-Marchant K, Miller ML. The preoperative bleeding time test:
17 assessing its clinical usefulness. *Cleve Clin J Med* 1995;62:379-82.
- 18 [8] Clinical and Laboratory Standards Institute (CLSI). Platelet Function Testing by
19 Aggregometry; Approved Guideline. Wayne, PA: CLSI 2008;1-45.
- 20 [9] Hartman MJ, Caccamese JF Jr, Bergman SA. Perioperative management of a patient with
21 Bernard-Soulier syndrome for third molar surgery. *Oral Surg Oral Med Oral Pathol Oral*
22 *Radiol Endod* 2007;103:626-9.
- 23 [10] Yoshiga D, Yoshida A, Kitahara S, Harada C, Ito S, Nakamura S, et al. Perioperative
24 management of a patient with Bernard-Soulier Syndrome that has a refractoriness to platelet
25 transfusion. *J Oral Maxillofac Surg Med Pathol* 2011;23:102-4.

1 **Legends**

2 **Fig. 1-a**

3 An oral examination revealed poor hygiene with redness and swelling of the maxillary and
4 mandibular gingiva and dental calculus on most teeth. Blood clots were observed around the
5 second right maxillary premolar.

6 **Fig. 1-b**

7 The second left maxillary molar was cracked and decayed to the dental pulp.

8 **Fig. 2**

9 Microscopic view of the peripheral blood smear. Giant platelets were detected; these platelets
10 were slightly larger than red blood cells.

11 **Fig. 3-a**

12 The extraction sites were packed with gelatine sponges.

13 **Fig. 3-b**

14 Used splint for hemostasis.

15 **Fig. 3-c**

16 Three days after extraction. Continuous bleeding from the palatal side of the gingival margin
17 and an infection of the buccal side of the gingival margin were identified at the extraction site.

18 **Fig. 4**

19 Flow cytometric analysis of platelets. Histograms present control platelets and those collected
20 from the patient before and after transfusion (A). The peak value for the control was
21 approximately 8 fL; those for the patient before and after transfusion were approximately 30–
22 40 fL (▼). This indicates that the patient's samples contained many giant platelets. A
23 post-transfusion sample exhibited an increase at approximately 8–10 fL, indicating the
24 addition of normal platelets from the transfusion (▼). A scattergram shows the control
25 platelets and those from the patient before and after transfusion (B). These data indicate that

1 the platelet size convergence was smaller for the control than for the patient (▼)

2 **Table 1**

3 Result of platelet examinations and blood coagulation tests.

4

5

6

7

8

9

10

11

12

13




Fig. 1 Intraoral photograph at the initial examination




Fig. 2 Microscopic view of the peripheral blood smear.



Fig. 3 Photograph of extraction sites and splint




Fig. 4 Flow cytometric analysis of platelets.

	tooth extraction day		3 days after tooth extraction	7 days after tooth extraction
	Before platelet transfusion	After platelet transfusion		
Platelet count (×10 ⁹ /L) impedance method	7	29	8	9
Platelet count (×10 ⁹ /L) optics method	17	37	25	31
^a PT (%)	129	99	79	92
PT (s)	11.4	12.1	13.2	12.4
PT ^b (INR)	0.93	1.01	1.10	1.03
^c APTT (s)	28.5	29.4	32.0	29.3

Aggregation with ristocetin	↓	↓	-	-
Skin bleeding time (min)	5	7.8	-	-
^d FIB (mg/dl)	230	-	281	-
Thrombotest (%)	181	-	116	-

- ^a PT, prothrombin time
- ^b INR, international normalized ratio
- ^c APTT, activated partial thromboplastin time
- ^d FIB, fibrinogen